Week of September 27th 2021 | Vol. 10, Issue 40 |
|
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US
Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
|
|
Startup Xealth banked $24 million in fresh funding led by Advocate Aurora Enterprises to help health systems scale up their digital health strategies.
With this latest round of financing, Xealth has raised $52.6 million.
“It’s a stepping stone toward building a better product vision,” Mike McSherry, CEO and co-founder of Xealth told Fierce Healthcare.
The funds will be used to expand Xealth’s operations, including adding staff and new customers, roughly doubling its size. Xealth has 60 employees now.
The fresh capital also will support product innovation, including enhancing the company's intelligence engine to help health systems determine which tools work best with which patients.
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
9 transactions totaling $4 million
Supplies, Equipment & Services
20 transactions totaling $2,354 million
Healthcare IT & Managed Care
3 transactions totaling $6 million
Healthcare Facilities & Distributors
6 transactions totaling $31 million
|
|
Pharma & Biotech
22 transactions totaling $360 million
Supplies, Equipment & Services
24 transactions totaling $1,052million
Healthcare IT & Managed Care
21 transactions totaling $1,608 million
Healthcare Facilities & Distributors
3 transaction totaling $106 million
|
|
Pharma & Biotech
14 transactions totaling $428 million
Supplies, Equipment & Services
13 transactions totaling $1,848million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
September 27, 2021 - Fierce Biotech
Delix Therapeutics, named a 2021 Fierce 15 winner today, has secured $70 million to bring two psychedelic analogs through phase 1 trials to treat brain disorders and boost its drug discovery work. The Boston-based biotech is riding on the tailwinds of the broader psychedelic and mental health spaces, both of which have seen increasing investor interest amid the COVID-19 pandemic. Delix, however, is creating "psychoplastogens," which don't carry the hallucinogenic and addictive qualities of psychedelics like LSD and MDMA.
September 28, 2021 - Fierce Pharma
Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-oncology megablockbuster Keytruda, but overlapping businesses could attract antitrust scrutiny, two analysts say. Merck is in advanced talks to buy Acceleron in what could be one of the New Jersey drugmaker’s biggest deals, The Wall Street Journal reported Monday, citing people familiar with the matter. The price tag would land around $180 per share for a total of over $11 billion, Bloomberg reported Friday.
September 29, 2021 - Fierce Biotech
Expansion Therapeutics thinks its RNA-modulating science can lead to drugs that potentially treat all the symptoms of certain neurodegenerative diseases, and it's reeled in $80 million from Big Pharmas and venture firms alike. Sanofi and Novartis' venture arms and high-profile life sciences investors like Cormorant, RA Capital, Westlake Village BioPartners, Logos Capital and others are backing that oversubscribed series B to bankroll Expansion's preclinical work. The proceeds will fund preclinical studies in myotonic dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
September 30, 2021 - Fierce Biotech
The ownership of SynCardia Systems, the sole manufacturer of the only FDA-approved total artificial heart, has changed hands—to a newcomer seemingly purpose-built for the effort. Hunniwell Lake Ventures has formed the portfolio company Picard Medical, which announced that it has acquired SynCardia and its assets for an undisclosed amount. Picard Medical takes its inspiration from the eponymous captain of the starship Enterprise, who—after being stabbed through the chest in a bar fight during his more rambunctious years—is known to carry an artificial heart of his own.
|
|
Events Hosted or Attended by Bourne Partners
Dates TBD - Charlotte, NC
October 5, 2021 - Virtual Webinar
November 9-11, 2021 - Milan, Italy
January 10-14, 2022 - San Francisco, CA
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
